Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Recommendation of “Hold” by Analysts

Shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) have earned a consensus rating of “Hold” from the five ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $38.3333.

A number of brokerages have commented on PHAR. Zacks Research raised Pharming Group from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. Weiss Ratings lowered Pharming Group from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, May 11th. Oppenheimer reaffirmed an “outperform” rating and issued a $41.00 price objective (down from $42.00) on shares of Pharming Group in a report on Friday, March 13th. HC Wainwright reaffirmed a “buy” rating and issued a $37.00 price objective on shares of Pharming Group in a report on Tuesday, March 24th. Finally, Wall Street Zen downgraded Pharming Group from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th.

Pharming Group Stock Performance

Shares of NASDAQ PHAR opened at $12.24 on Friday. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.63 and a quick ratio of 2.06. The stock’s fifty day moving average price is $15.19 and its two-hundred day moving average price is $16.37. Pharming Group has a one year low of $9.54 and a one year high of $21.34. The firm has a market cap of $864.39 million, a price-to-earnings ratio of 76.50 and a beta of -0.04.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.12). Pharming Group had a net margin of 3.30% and a return on equity of 4.64%. The firm had revenue of $72.45 million during the quarter, compared to analyst estimates of $92.06 million. On average, equities analysts forecast that Pharming Group will post 0.6 EPS for the current year.

Institutional Trading of Pharming Group

A number of institutional investors have recently modified their holdings of the stock. NewEdge Advisors LLC lifted its position in shares of Pharming Group by 11,310.3% during the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after acquiring an additional 28,615 shares during the period. Millennium Management LLC bought a new stake in shares of Pharming Group during the 4th quarter valued at $360,000. SmartHarvest Portfolios LLC bought a new stake in shares of Pharming Group during the 4th quarter valued at $224,000. Finally, EverSource Wealth Advisors LLC bought a new stake in shares of Pharming Group during the 2nd quarter valued at $32,000. 0.03% of the stock is currently owned by institutional investors.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.